The relationship between endocrine disruptors and erectile dysfunction has moved, over roughly fifteen years, from speculative toxicology to a body of human epidemiology that clinicians can no longer dismiss. Endocrine-disrupting chemicals (EDCs) are synthetic compounds that interfere with hormone synthesis, transport, receptor binding, or clearance. Two of the most widely studied — bisphenol A (BPA) and the phthalate ester family — are present in food packaging, thermal receipt paper, epoxy can linings, vinyl flooring, and personal care products, and are detectable in the urine of the overwhelming majority of adults in industrialised countries. The question for men's health is narrower and more practical: does measurable exposure to these compounds track with worse erectile function, and if so, by what mechanism?
What Endocrine Disruptors Are, and Where Exposure Comes From
BPA is a monomer used to manufacture polycarbonate plastics and epoxy resins. It leaches into food and beverages from can linings and hard plastic containers, particularly under heat. Phthalates are plasticisers used to make polyvinyl chloride flexible; the high-molecular-weight members, notably di(2-ethylhexyl) phthalate (DEHP), dominate exposure from food contact materials, while low-molecular-weight phthalates such as diethyl phthalate appear in fragrances and cosmetics.
Neither compound persists in the body the way organochlorines do. Both have biological half-lives measured in hours, which means urinary concentrations reflect recent rather than cumulative exposure. That short half-life has complicated the epidemiology considerably: a single spot urine sample is a noisy proxy for a person's habitual exposure, and misclassification of that kind tends to bias associations toward the null. When positive associations survive that noise, they warrant attention.
The mechanistic concern is that BPA behaves as a weak estrogen receptor agonist and an androgen receptor antagonist, while several phthalate metabolites suppress testicular steroidogenesis by downregulating the enzymes that convert cholesterol to testosterone in Leydig cells. A comprehensive review of in vitro, animal, and epidemiological work on BPA found consistent effects on male reproductive endpoints across experimental models, with human data more heterogeneous but directionally aligned.
The Occupational Evidence on BPA and Male Sexual Function
The clearest human signal comes from an unusual study population: Chinese factory workers with occupational BPA exposure two to three orders of magnitude above background. Li and colleagues compared BPA-exposed workers with unexposed controls from the same regions using standardised male sexual function inventories. Exposed workers showed consistently higher risk of sexual dysfunction across every measured domain — erectile difficulty, reduced ejaculation strength, lower sexual desire, and diminished overall satisfaction. The authors described their findings as the first human evidence that workplace BPA exposure adversely affects male sexual function.
A companion analysis from the same cohort examined the dose-response question directly, correlating urinary BPA concentration with sexual function scores. Increasing urine BPA level was associated with declining function across multiple domains after adjustment for confounders, and the gradient held within the exposed group rather than depending solely on the exposed-versus-unexposed contrast. A dose-response relationship of that kind is one of the stronger arguments against pure confounding.
The obvious caveat is generalisability. Occupational exposure in a polycarbonate plant is not the exposure a man gets from a receipt and a tin of tomatoes. Studies at general-population exposure levels have produced weaker and less consistent results, which is what one would expect if the relationship is real but dose-dependent, and also what one would expect if it is an artefact of the occupational setting. The honest reading is that high exposure is associated with sexual dysfunction and that the threshold below which it stops mattering has not been established.
Phthalates, Testosterone, and the Androgen Axis
Phthalate research has focused less on erectile function directly and more on the hormone that underpins it. Meeker and Ferguson analysed thirteen urinary phthalate metabolites against serum total testosterone in NHANES 2011-2012, stratifying by sex and age band. They reported inverse associations between several metabolites and circulating testosterone, with the associations varying by age group — a pattern consistent with differing susceptibility across the lifespan rather than a uniform toxic effect.
A later NHANES analysis by Woodward and colleagues covering 2013-2016 sharpened the picture. Across all men, phthalate metabolites were not significantly associated with sex hormone concentrations. But in older men specifically, each doubling of summed DEHP metabolites corresponded to approximately 7.7% lower total testosterone. The null result in the pooled analysis alongside a significant effect in the older stratum is a useful reminder that these exposures likely interact with age-related decline in testicular reserve rather than acting independently of it.
A 2026 multi-omics synthesis of DEHP-associated male reproductive toxicity integrated population studies with animal and molecular data, and reported convergent evidence linking DEHP exposure to testosterone deficiency in adult men. Converging lines of evidence from different study designs are more persuasive than any single epidemiological association, though the human effect sizes remain modest.
Low testosterone is not itself a common cause of erectile dysfunction, but it contributes meaningfully to libido, to nocturnal erections, and to the responsiveness of penile tissue to nitric oxide signalling. A 7-8% reduction in total testosterone will not, on its own, produce erectile dysfunction in a healthy man. In a man already at the lower end of the reference range, with a degree of vascular compromise, it is one more variable pushing in the wrong direction.
The Vascular and Metabolic Pathway
The second mechanism by which endocrine disruptors and erectile dysfunction may be linked has nothing to do with hormone receptors directly. Erection is fundamentally a vascular event, dependent on endothelial nitric oxide release and adequate arterial inflow. Anything that impairs endothelial function impairs erection.
Stahlhut and colleagues, analysing NHANES data on adult US males, found that urinary phthalate metabolite concentrations were associated with increased waist circumference and with insulin resistance as measured by HOMA-IR. Both are established drivers of endothelial dysfunction, and both are among the strongest predictors of erectile dysfunction in middle-aged men. If phthalate exposure contributes even marginally to central adiposity and impaired insulin sensitivity, it contributes to the same vascular pathology that produces erectile symptoms a decade later.
This matters for interpretation. It suggests that the plausible effect of everyday EDC exposure on erectile function is indirect, slow, and mediated through metabolic and vascular health — not a direct chemical assault on erectile tissue. That framing is less alarming but arguably more useful, because it places EDC exposure alongside the other modifiable cardiometabolic contributors rather than in a category of its own.
What This Means in Practice
Reasonable exposure reduction is inexpensive and carries no downside: avoid heating food in plastic, store leftovers in glass or stainless steel, choose fresh or frozen over canned where practical, and decline thermal receipts. These measures demonstrably lower urinary BPA and phthalate concentrations. Whether they improve erectile function has never been tested in a randomised trial, and it would be dishonest to imply otherwise.
What deserves more emphasis is the clinical corollary. If a man in his forties or fifties develops erectile difficulty, the diagnostic priority is not his plastic exposure. It is blood pressure, fasting glucose or HbA1c, lipids, and morning testosterone — because erectile dysfunction is frequently the first symptomatic expression of endothelial disease, preceding cardiac events by an average of three to five years. Chasing an environmental explanation while leaving an untreated metabolic one is the more consequential error. Readers can find related discussions of the vascular and metabolic contributors across the OnyxMD blog.
Conclusion
The evidence connecting endocrine disruptors and erectile dysfunction is real but graded. Occupational-level BPA exposure shows a consistent, dose-dependent association with male sexual dysfunction. Phthalate exposure, particularly DEHP, shows modest inverse associations with testosterone that appear concentrated in older men, and associations with the central adiposity and insulin resistance that drive vascular erectile dysfunction. What has not been shown is that background-level exposure causes erectile dysfunction in an otherwise healthy man, or that reducing exposure reverses established symptoms. Clinical studies suggest a contributory role within a multifactorial condition, and some men may be more susceptible than others.
For men whose symptoms are already established, the productive question is what is driving the vascular and hormonal picture now, and what treatment is appropriate. If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com, including the daily formulation reviewed at EPIQ CHEWS.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Li D, Zhou Z, Qing D, et al. Occupational exposure to bisphenol-A (BPA) and the risk of self-reported male sexual dysfunction. Human Reproduction. 2010;25(2):519-527. doi:10.1093/humrep/dep381
- Li DK, Zhou Z, Miao M, et al. Relationship between urine bisphenol-A level and declining male sexual function. Journal of Andrology. 2010;31(5):500-506. doi:10.2164/jandrol.110.010413
- Meeker JD, Ferguson KK. Urinary phthalate metabolites are associated with decreased serum testosterone in men, women, and children from NHANES 2011-2012. Journal of Clinical Endocrinology and Metabolism. 2014;99(11):4346-4352. doi:10.1210/jc.2014-2555
- Woodward MJ, Obsekov V, Jacobson MH, Kahn LG, Trasande L. Phthalates and sex steroid hormones among men from NHANES, 2013-2016. Journal of Clinical Endocrinology and Metabolism. 2020;105(4):e1225-e1234. doi:10.1210/clinem/dgaa039
- Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environmental Health Perspectives. 2007;115(6):876-882. doi:10.1289/ehp.9882
- Gong Z, Feng Q, Chen W, Xu C, Tang S, Liu S. DEHP-induced male reproductive toxicity: evidence from population studies, animal experiments, and multi-omics profiling. Ecotoxicology and Environmental Safety. 2026;322:120320. doi:10.1016/j.ecoenv.2026.120320
- Tomza-Marciniak A, Stepkowska P, Kuba J, Pilarczyk B. Effect of bisphenol A on reproductive processes: a review of in vitro, in vivo and epidemiological studies. Journal of Applied Toxicology. 2018;38(1):51-80. doi:10.1002/jat.3480
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.